AzPA Pharmacy Flash

• Darolutamide Receives FDA Approval for mCSPC
  The FDA has approved darolutamide for treating metastatic hormone-sensitive prostate cancer, based on a phase three randomized trial, demonstrating its efficacy in metastatic hormone-sensitive prostate cancer treatment.
• Pharmacogenomics Offers Roadmap for Integrating Genetics Into Personalized Medicine
  Pharmacogenomics is a new frontier in precision medicine, allowing treatments to be tailored to individual patient genetic profiles. Pharmacogenomics services require strategies, reimbursement and education to improve patient outcomes.
• FDA Approves Expanded Use of 'Powerful' Lung Imaging Tool
  The U.S. FDA has approved Xenoview, a hyperpolarized contrast agent, for expanded use in pediatric patients, allowing around one million more patients to receive it for lung ventilation evaluation.